CLINICAL TRIALS PROFILE FOR DUEXIS
✉ Email this page to a colleague
All Clinical Trials for DUEXIS
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT01563185 ↗ | Open-label Safety and Pharmacokinetic Study of DUEXIS® (Ibuprofen and Famotidine) Tablets in Juvenile Idiopathic Arthritis | Completed | Pediatric Rheumatology Collaborative Study Group | Phase 4 | 2012-04-01 | The primary objective of this Phase 4, multi-center, open-label study is to evaluate the safety and tolerability of DUEXIS in Juvenile Idiopathic Arthritis (JIA) patients aged 10 years to 16 years, 11 months, treated up to 24 weeks. The secondary objectives are to evaluate the PK characteristics of DUEXIS in JIA patients and to evaluate the signs and symptoms of JIA in patients aged 10 years to 16 years, 11 months receiving DUEXIS for up to 24 weeks. |
NCT01563185 ↗ | Open-label Safety and Pharmacokinetic Study of DUEXIS® (Ibuprofen and Famotidine) Tablets in Juvenile Idiopathic Arthritis | Completed | Horizon Pharma Ireland, Ltd., Dublin Ireland | Phase 4 | 2012-04-01 | The primary objective of this Phase 4, multi-center, open-label study is to evaluate the safety and tolerability of DUEXIS in Juvenile Idiopathic Arthritis (JIA) patients aged 10 years to 16 years, 11 months, treated up to 24 weeks. The secondary objectives are to evaluate the PK characteristics of DUEXIS in JIA patients and to evaluate the signs and symptoms of JIA in patients aged 10 years to 16 years, 11 months receiving DUEXIS for up to 24 weeks. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for DUEXIS
Condition Name
Clinical Trial Locations for DUEXIS
Trials by Country
Clinical Trial Progress for DUEXIS
Clinical Trial Phase
Clinical Trial Sponsors for DUEXIS
Sponsor Name